Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 b…
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 b…
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 3…
. New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31,…
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an ove…
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17…
TÜV SÜD Schweiz AG has acquired the process safety laboratory of Lonza Ltd. at its Visp site, Switzerland. By expanding…
Die TÜV SÜD Schweiz AG hat das Labor für Prozesssicherheit der Lonza AG am Standort Visp in der Schweiz übernommen. Durc…